Talis Biomedical Corporation Common Stock
TLIS
TLIS was delisted on the 30th of August, 2024.
18 hedge funds and large institutions have $6.93M invested in Talis Biomedical Corporation Common Stock in 2024 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 5 increasing their positions, 3 reducing their positions, and 2 closing their positions.
67% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 3
50% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 2
17% more capital invested
Capital invested by funds: $5.93M → $6.93M (+$1,000K)
0% more funds holding
Funds holding: 18 → 18 (0)
0.22% less ownership
Funds ownership: 43.77% → 43.55% (-0.22%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$84.9K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$15.3K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$5.03K |
| 4 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
+$2.47K |
| 5 |
Morgan Stanley
New York
|
+$2.18K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$74.7K |
| 2 |
BlackRock
New York
|
-$47.2K |
| 3 |
Citigroup
New York
|
-$12.1K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$503 |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$58 |
TLIS Hedge Fund Activity: Q1 2024 in Review
18 of the 6,958 institutional investors tracked by Wall St. Rank reported a position in Talis Biomedical Corporation Common Stock (TLIS) for Q1 2024, worth a combined $6.93M — up 17% from $5.93M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new TLIS positions and 2 closed out — a net gain of 1 holder — while 5 added to existing stakes and 3 trimmed.
The largest buyer was Renaissance Technologies, opening a new position worth an estimated $84.9K. The largest seller was Citadel Advisors, exiting entirely with an estimated $74.7K sold.
- 18 institutional investors held Talis Biomedical Corporation Common Stock (TLIS) as of Q1 2024, unchanged from Q4 2023.
- Funds reported $6.93M of Talis Biomedical Corporation Common Stock stock for Q1 2024, up 17% quarter-over-quarter.
- 3 funds opened new Talis Biomedical Corporation Common Stock positions in Q1 2024 and 2 closed out, a net change of +1 holder.
- The largest Talis Biomedical Corporation Common Stock buyer in Q1 2024 was Renaissance Technologies, an estimated $84.9K added.
- The largest Talis Biomedical Corporation Common Stock seller in Q1 2024 was Citadel Advisors, an estimated $74.7K sold.
Based on aggregated 13F filings for Q1 2024.